<P>The homing of natural killer (NK) cells is often inhibited by pancreatic cancer tumors. A mesothelin-directed antibody conjugated to a cleavable NK cell—recruiting chemokine increased NK-cell infiltration of PDAC tumors, reduced tumor ...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A107442850
2019
-
SCOPUS,SCIE
학술저널
219-229(11쪽)
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
<P>The homing of natural killer (NK) cells is often inhibited by pancreatic cancer tumors. A mesothelin-directed antibody conjugated to a cleavable NK cell—recruiting chemokine increased NK-cell infiltration of PDAC tumors, reduced tumor ...
<P>The homing of natural killer (NK) cells is often inhibited by pancreatic cancer tumors. A mesothelin-directed antibody conjugated to a cleavable NK cell—recruiting chemokine increased NK-cell infiltration of PDAC tumors, reduced tumor burden, and improved survival.</P><P>Natural killer (NK) cells are primary immune cells that target cancer cells and can be used as a therapeutic agent against pancreatic cancer. Despite the usefulness of NK cells, NK-cell therapy is limited by tumor cell inhibition of NK-cell homing to tumor sites, thereby preventing a sustained antitumor immune response. One approach to successful cancer immunotherapy is to increase trafficking of NK cells to tumor tissues. Here, we developed an antibody-based NK-cell–homing protein, named NK-cell–recruiting protein-conjugated antibody (NRP-body). The effect of NRP-body on infiltration of NK cells into primary and metastatic pancreatic cancer was evaluated <I>in vitro</I> and in murine pancreatic ductal adenocarcinoma models. The NRP-body increased NK-cell infiltration of tumors along a CXCL16 gradient (CXCL16 is cleaved from the NRP-body by furin expressed on the surface of pancreatic cancer cells). CXCL16 induced NK-cell infiltration by activating RhoA via the ERK signaling cascade. Administration of the NRP-body to pancreatic cancer model mice increased tumor tissue infiltration of transferred NK cells and reduced the tumor burden compared with that in controls. Overall survival of NRP-body–treated mice (even the metastasis models) was higher than that of mice receiving NK cells alone. In conclusion, increasing NK-cell infiltration into tumor tissues improved response to this cancer immunotherapy. The combination of an NRP-body with NK-cell therapy might be useful for treating pancreatic cancer.</P>